Biotechnology company GenScript Biotech BV announced on Wednesday that it has entered into an agreement for the exclusive distribution of its GenScript cPass SARS-CoV-2 Neutralization Antibody Detection Kit in Spain, Portugal through Andorra IES Diagnostics, a life science company.

The GenScript cPass SARS-CoV-2 Neutralization Antibody Detection test reportedly measures the presence of neutralizing antibodies (NAbs) in patients recovering from COVID-19 or receiving a vaccine.

In addition, the GenScript cPass SARS-CoV-2 Neutralization Antibody Detection test is the only US FDA Emergency Use Authorized (EUA) serology test for neutralizing antibodies from recent and prior SARS-CoV-2 infections.

According to the company, the kit is CE marked (Europe), with HSA provisional approval in Singapore, ANVISA in Brazil, ANMAT in Argentina and clearance from the Ministry of Health and Prevention (MOHAP) in the United Arab Emirates as a medical device.